Clinical trials: Lipoprotein(a), open to volunteers
Elevated Lipoprotein(a)
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0195 Injection in Participants With or Without Elevated Lipoprotein(a)
This is a randomized, double-blind, placebo-controlled, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of SAL0195 injection in participants with or without…
- Trial name
- NCT07804160
- Testing
- SAL0195 Injection 30 mg, SAL0195 Injection 100 mg, SAL0195 Injection 300 mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Hyperlipoproteinemia (a)
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or…
- Trial name
- NCT07172646
- Testing
- SRSD216 injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Lipoprotein Disorder, Arterial Stiffness
The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation
1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a). 2.
- Conditions
- Lipoprotein Disorder, Arterial Stiffness, Endothelial Dysfunction
- Trial name
- Lpa_endo (NCT07324902)
- Where
- 2 sites in Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Athens
Coronary Artery Disease (CAD), Computed Tomography Angiography
AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)
The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated…
- Conditions
- Coronary Artery Disease (CAD), Computed Tomography Angiography, Biomarkers, AI (Artificial Intelligence)
- Trial name
- ACTION (NCT07577609)
- Where
- Ireland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Galway
Fatty Acids, Omega-3, Fish Oils
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Background: Fish oils contain omega-3 fatty acids that play important roles in the body. Researchers are studying a new type of fish oil that contains very-long-chain omega-3 fatty acids (VLCPUFAs).
- Trial name
- NCT07882160
- Testing
- VLCPUFA-rich fish oil, DHA-rich fish oil
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Prevention
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy
The Lp(a)-PLAT Study is designed to close a critical evidence gap in cardiovascular prevention for the roughly 20% of the population who carry genetically determined elevations in lipoprotein(a) - a recognised pro-thrombotic and…
- Trial name
- Lp(a)-PLAT (NCT07720934)
- Testing
- Aspirin, Clopidogrel
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- François MACH
Hyperlipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAL0167 following single and multiple dose administration in healthy participants.
- Trial name
- NCT07722299
- Testing
- SAL0167 group
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Type 1 Diabetes
The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D).
- Trial name
- HAGI-T1D (NCT07564752)
- Testing
- Blood test, Urine sample
- Where
- France
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Healthy
Low-carbohydrate Diet and Low-Density Lipoprotein - Cholesterol (LDL-c) Interindividual Variability
Ketogenic diets are very low-carbohydrate diets that increase hepatic production of ketone bodies, which have several effects as substrates and signals.
- Trial name
- REPETO (NCT07675603)
- Testing
- control diet, Low carbohydrate diet
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Bath
Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
Pharmacokinetics and Pharmacodynamics Study
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.
- Trial name
- NCT07074236
- Testing
- QLC7401 injection, RBD7022 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lipoprotein(a)
A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)
The main purpose of this study will evaluate how the body takes in lepodisiran (LY3819469) after a single injection under the skin. Researchers will compare how much lepodisiran gets into the body from each injection site.
- Trial name
- NCT07914738
- Testing
- LY3819469
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults
The purpose of this clinical trial is to find out whether one type of fish oil works better than another at improving metabolic health in people who are at high risk of developing type 2 diabetes.
- Conditions
- Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetes / Type 2 Diabetes, Obesity & Overweight
- Trial name
- END-T2D (NCT07575438)
- Testing
- Fish Oil, Corn oil control
- Where
- Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- May Faraj, PDt, PhD